FDA warns of foot, leg amputations with Invokana
Patients with type 2 diabetes taking Johnson & Johnson’s drug Invokana are twice as likely to have a leg and foot amputation than patients given a placebo, two clinical trial show.
The FDA recently required J&J to add a black box warning, reserved for the most serious possible adverse events, to Invokana (Invoking, Invokanmet and Invokamet XR) also known as canagliflozin.
Invokana is also subject to litigation for another serious side effect, severe kidney damage.
Previous blog post on Invokana:FDA Warnings on SGLT2 Diabetes Drugs.